Fluvoxamine Maleate, chemically defined as 2-[[[(1E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxy]ethanamine (Z)-butenedioate, is the maleate salt of Fluvoxamine, a monocyclic (non-tricyclic) selective serotonin reuptake inhibitor (SSRI) that is also a sigma-1 receptor agonist, with molecular formula C₁₅H₂₁F₃N₂O₂·C₄H₄O₄ (C₁₉H₂₅F₃N₂O₆) and molecular weight 434.41 g/mol (free base 318.34 g/mol). Structurally, the molecule features a 4-(trifluoromethyl)phenyl-substituted oxime ether backbone with (E)-configuration at the C=N bond; the corresponding (Z)-isomer is a known photo-isomerization impurity, and the maleate salt provides a stable, crystalline solid form suitable for oral tablets. Pharmacologically, selective inhibition of presynaptic serotonin reuptake underlies its therapeutic use in obsessive-compulsive disorder and, in many markets, major depressive disorder and anxiety disorders. Supplied by Chemicea as a well-characterized, high-purity reference standard, it supports analytical method development, assay and related-substance testing, dissolution and stability studies, and quality-control testing throughout Fluvoxamine Maleate drug substance and formulation development, in line with EP, BP, and USP monograph requirements. Each batch is supplied with a comprehensive Certificate of Analysis supported by HPLC, ¹H-NMR, and Mass Spectrometry characterization data, ensuring dependable analytical traceability for regulatory and R&D applications. CAS No. 61718-82-9 (free base CAS No. 54739-18-3) | Explore complete technical documentation, Safety Data Sheet (SDS), and pricing.